WO2022010847A1 - Mic antibodies and binding agents and methods of using the same - Google Patents

Mic antibodies and binding agents and methods of using the same Download PDF

Info

Publication number
WO2022010847A1
WO2022010847A1 PCT/US2021/040445 US2021040445W WO2022010847A1 WO 2022010847 A1 WO2022010847 A1 WO 2022010847A1 US 2021040445 W US2021040445 W US 2021040445W WO 2022010847 A1 WO2022010847 A1 WO 2022010847A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding agent
amino acid
seq
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/040445
Other languages
English (en)
French (fr)
Inventor
Jennifer Donglan WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CanCure LLC
Original Assignee
CanCure LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2022578860A priority Critical patent/JP2023532852A/ja
Priority to KR1020227046132A priority patent/KR102594083B1/ko
Priority to KR1020237036123A priority patent/KR20230152783A/ko
Priority to CA3184940A priority patent/CA3184940A1/en
Priority to EP21748734.7A priority patent/EP4178678A1/en
Priority to CN202180047612.4A priority patent/CN116249716A/zh
Application filed by CanCure LLC filed Critical CanCure LLC
Priority to AU2021305084A priority patent/AU2021305084A1/en
Publication of WO2022010847A1 publication Critical patent/WO2022010847A1/en
Priority to US18/049,434 priority patent/US12139539B2/en
Anticipated expiration legal-status Critical
Priority to US18/909,119 priority patent/US20250026837A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the binding agent is an antibody or an antigen-binding portion thereof.
  • the binding agent is a monoclonal antibody, a Fab, a Fab', a F(ab'), an Fv, a disulfide linked Fc, an scFv, a single domain antibody, a diabody, a bi-specific antibody, or a multi-specific antibody.
  • the cancer is a carcinoma, a sarcoma, a neuroendocrine tumor, or a hematologic malignancy.
  • the carcinoma is a solid tumor, optionally selected from melanoma, prostate cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, colon cancer, kidney cancer, and head and neck cancer.
  • the hematologic malignancy is a lymphoma, leukemia, or multiple myeloma.
  • An epitope defines the minimum binding site for an antibody or other binding agent, and thus represent the target of specificity of an antibody, antigen binding portion thereof or other immunoglobulin-based binding agent.
  • an epitope represents the unit of structure bound by a variable domain in isolation.
  • a MIC antibody or antigen binding portion thereof or other binding agent as described herein specifically binds to a MIC polypeptide with a dissociation constant (KD) of from about 10 -6 M to 10 -7 M. In some embodiments, a MIC antibody or antigen-binding portion thereof or other binding agent as described herein specifically binds to a MIC polypeptide with a dissociation constant (KD) of from about 10 -7 M to 10 -8 M. In some embodiments, a MIC antibody or antigen-binding portion thereof or other binding agent as described herein specifically binds to a MIC polypeptide with a dissociation constant (KD) of from about 10 -8 M to 10 -9 M.
  • KD dissociation constant
  • a binding agent comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises a complementarity determining region HCDR1 having the amino acid sequence set forth in SEQ ID NO:11, a HCDR2 having the amino acid sequence set forth in SEQ ID NO:12 and a HCDR3 having the amino acid sequence set forth in SEQ ID NO:13, and wherein the VH region comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1.
  • the polydispersity index (PDI) of MIC antibodies may be less than 0.1, as determined by DLS.
  • a MIC antibody or antigen binding portion or other binding agent has (i) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 1 , and (ii) a light chain variable region having the amino acid sequence set forth in SEQ ID NO:2, and has an optionally substituted framework region as described herein, and competes for specific binding with the antibody B10G5 that specifically binds to a conformational epitope on MICA and MICB location within about amino acid 66-77, 136-144 and 247-258 of the amino acid sequence set forth in SEQ ID NO:27 and 28.
  • Each VH and VL region thus consists of three CDRs and four FRs that are arranged from the N terminus to the C terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. This structure is well known to those skilled in the art.
  • a MIC antibody heavy chain is of the IgGI isotype and has the amino acid sequence set forth in SEQ ID NO:7.
  • a MIC antibody light chain is of the kappa isotype and has the amino acid sequence set forth in SEQ ID NO:8.
  • a conservatively modified variant of a MIC antibody or antigen binding portion thereof can have alterations in the FR (i.e. , other than in the CDRs), e.g. a conservatively modified variant of a MIC antibody has the amino acid sequences of the VH and VL CDRs (set forth in SEQ ID NOs: 11-16) and has at least one conservative amino acid substitution in the FR.
  • amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), lie (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (C); (3) acidic: Asp (D), Glu (E); and (4) basic: Lys (K), Arg (R), His (H).
  • Such a modification or series of modifications to an Fc domain or region can permit selective binding of an Fc domain to FcRs on immune cells, or can reduce or eliminate the interaction of an antibody or antigen binding portion having the modified domain with immune cells.
  • modifications to an Fc domain can reduce binding of an Fc domain to Fc gamma receptors, but retain the ability of the Fc domain to bind to FcRn.
  • a modification can be a substitution of P238, such as P238A, according to the EU index of Kabat.
  • a modification can be a substitution of D265, such as D265A, according to the EU index of Kabat.
  • a modification can be a substitution of N297, such as N297A, according to the EU index of Kabat.
  • a modification can be a substitution of A327, such as A327Q, according to the EU index of Kabat.
  • a modification can be a substitution of P329, such as P239A, according to the EU index of Kabat.
  • a modification comprises substitution of one or more amino acids that decreases binding affinity of an IgG Fc domain or region to FcyRII receptor and increases the binding affinity to FcyRIIIA receptor.
  • a modification can be a substitution of S298, such as S298A, according to the EU index of Kabat.
  • a modification can be substitution of S239, I332 and A330, such as S239D/I332E/A330L.
  • a modification can be substitution of S239 and 1332, such as S239D/I332E.
  • a modification can comprise a substitution of one amino acid residue that increases the binding affinity of an IgG Fc domain for FcRn, relative to a wildtype or reference IgG Fc domain.
  • a modification can comprise a substitution at V308, such as V308P according to the EU index of Kabat.
  • a modification can comprise a substitution at M428, such as M428L according to the EU index of Kabat.
  • a modification can comprise a substitution at N434, such as N434A according to the EU index of Kabat or N434H according to the EU index of Kabat.
  • a MIC antibody or antigen-binding portion thereof as described herein can occur in either prokaryotic or eukaryotic cells.
  • Suitable hosts include bacterial or eukaryotic hosts, including yeast, insects, fungi, bird and mammalian cells either in vivo, or in situ, or host cells of mammalian, insect, bird or yeast origin.
  • the mammalian cell or tissue can be of human, primate, hamster, rabbit, rodent, cow, pig, sheep, horse, goat, dog or cat origin, but any other mammalian cell may be used.
  • an antibody or antigen-binding portion thereof (e.g., a VH having the amino acid sequence set forth in SEQ ID NO:1 and/or a VL having the amino acid sequence set forth in SEQ ID NO:2 or a variant thereof as described herein) is produced in a cell-free system.
  • a cell-free system Non-limiting exemplary cell-free systems are described, e.g., in Sitaraman et al., Methods Mol. Biol. 498: 229-44 (2009); Spirin, Trends Biotechnol. 22: 538-45 (2004); Endo et al., Biotechnol. Adv. 21: 695-713 (2003).
  • Intact (e.g., whole) antibodies, their dimers, individual light and heavy chains, or antigen binding portions thereof can be recovered and purified by known techniques, e.g., immunoadsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), ammonium sulfate precipitation, gel electrophoresis, or any combination of these. See generally, Scopes, Protein Purification (Springer-Verlag, N.Y., 1982). Substantially pure MIC binding antibodies or antigen binding portions thereof of at least about 90% to 95% homogeneity are advantageous, as are those with 98% to 99% or more homogeneity, particularly for pharmaceutical uses.
  • Suitable anti-PD-1 and anti-PD-L1 therapy agents include, for example, anti-PD-1 and anti-PD-L1 antibodies, human anti-PD-1 and anti-PD-L1 antibodies, mouse anti-PD-1 and anti- PD-L1 antibodies, mammalian anti-PD-1 and anti-PD-L1 antibodies, humanized anti-PD-1 and anti-PD-L1 antibodies, monoclonal anti-PD-1 and anti-PD-L1 antibodies, polyclonal anti-PD-1 and anti-PD-L1 antibodies, chimeric anti-PD-1 and anti-PD-L1 antibodies, anti-PD-1 adnectins and anti-PD-L1 adnectins, anti-PD-1 domain antibodies and anti-PD-L1 domain antibodies, single chain anti-PD-1 mAbs and single chain anti-PD-L1 mAbs, heavy chain anti-PD-1 mAbs and heavy chain anti-PD-L1 mAbs, and light chain anti-PD-1 mAbs and light chain anti-PD-
  • the checkpoint inhibitor is Ipilimumab (Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Avelumab (Bavencio), or Durvalumab (Imfinzi).
  • the adoptive cell therapy comprises autologous NK cells, allogeneic NK cells, autologous T cells, CAR modified T cells and CAR modified NK cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2021/040445 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same Ceased WO2022010847A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020227046132A KR102594083B1 (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법
KR1020237036123A KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법
CA3184940A CA3184940A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same
EP21748734.7A EP4178678A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same
CN202180047612.4A CN116249716A (zh) 2020-07-07 2021-07-06 Mic抗体和结合剂及其使用方法
JP2022578860A JP2023532852A (ja) 2020-07-07 2021-07-06 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法
AU2021305084A AU2021305084A1 (en) 2020-07-07 2021-07-06 MIC antibodies and binding agents and methods of using the same
US18/049,434 US12139539B2 (en) 2020-07-07 2022-10-25 MIC antibodies and binding agents and methods of using the same
US18/909,119 US20250026837A1 (en) 2020-07-07 2024-10-08 MIC Antibodies and Binding Agents and Methods of Using the Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/049,434 Continuation US12139539B2 (en) 2020-07-07 2022-10-25 MIC antibodies and binding agents and methods of using the same

Publications (1)

Publication Number Publication Date
WO2022010847A1 true WO2022010847A1 (en) 2022-01-13

Family

ID=77127088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/040445 Ceased WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Country Status (9)

Country Link
US (2) US12139539B2 (enExample)
EP (1) EP4178678A1 (enExample)
JP (1) JP2023532852A (enExample)
KR (2) KR102594083B1 (enExample)
CN (1) CN116249716A (enExample)
AU (1) AU2021305084A1 (enExample)
CA (1) CA3184940A1 (enExample)
TW (1) TW202216776A (enExample)
WO (1) WO2022010847A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023076883A1 (en) * 2021-10-27 2023-05-04 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
WO2023225626A3 (en) * 2022-05-20 2024-06-13 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5977318A (en) 1991-06-27 1999-11-02 Bristol Myers Squibb Company CTLA4 receptor and uses thereof
WO1999063050A2 (en) 1998-06-02 1999-12-09 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
WO2001039594A2 (en) 1999-12-03 2001-06-07 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
WO2001074855A2 (en) 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20020039581A1 (en) 2000-01-27 2002-04-04 Carreno Beatriz M. Antibodies against CTLA4 and uses therefor
US20020086014A1 (en) 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2006103569A2 (en) 2005-03-18 2006-10-05 Innate Pharma Expression vectors and methods for obtaining nk cell specific expression
US20060270045A1 (en) 2003-10-22 2006-11-30 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014153270A1 (en) 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015164675A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016033570A1 (en) 2014-08-28 2016-03-03 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for cd19
WO2016064929A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016176651A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016201304A1 (en) 2015-06-10 2016-12-15 Nantkwest, Inc. Modified nk-92 cells for treating cancer
WO2017100709A1 (en) 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
US9803023B2 (en) 2004-11-12 2017-10-31 Xencor, Inc. Fc variants with altered binding to FcRn
WO2018165291A1 (en) 2017-03-08 2018-09-13 Nantkwest, Inc. MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
WO2018183385A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019018603A2 (en) 2017-07-19 2019-01-24 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
WO2019028337A1 (en) 2017-08-04 2019-02-07 Nantkwest, Inc. TREATMENT AND INHIBITION OF LEUKEMIA USING NK-92 CELLS
WO2019032929A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2020033927A2 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
CA2747011C (en) 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
SI2760471T1 (sl) 2011-09-30 2017-04-26 Dana-Farber Cancer Institute, Inc. Terapevtski peptidi
CA2862101A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
US20170198054A1 (en) 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
AU2016362597C1 (en) 2015-12-04 2022-05-26 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
AU2017344411A1 (en) 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2020028428A2 (en) 2018-07-31 2020-02-06 Pdi Therapeutics, Inc. Anti-mica/b antibodies that block mica/b shedding and methods of use
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Vor Biopharma, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
JP7689744B2 (ja) 2019-08-23 2025-06-09 ノースウェスタン ユニバーシティ 抗原特異的ｔ細胞応答を活性化するための材料および方法
CN118414352A (zh) 2021-10-27 2024-07-30 美国株式会社三养生物制药 具有变体fc结构域的抗-mic抗体

Patent Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5977318A (en) 1991-06-27 1999-11-02 Bristol Myers Squibb Company CTLA4 receptor and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6207156B1 (en) 1997-03-21 2001-03-27 Brigham And Women's Hospital, Inc. Specific antibodies and antibody fragments
WO1999063050A2 (en) 1998-06-02 1999-12-09 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7132281B2 (en) 1998-12-23 2006-11-07 Amgen Fremont Inc. Methods and host cells for producing human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US20050201994A1 (en) 1999-08-24 2005-09-15 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20020086014A1 (en) 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
WO2001039594A2 (en) 1999-12-03 2001-06-07 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
US20020039581A1 (en) 2000-01-27 2002-04-04 Carreno Beatriz M. Antibodies against CTLA4 and uses therefor
WO2001074855A2 (en) 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
US20060270045A1 (en) 2003-10-22 2006-11-30 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US9803023B2 (en) 2004-11-12 2017-10-31 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006103569A2 (en) 2005-03-18 2006-10-05 Innate Pharma Expression vectors and methods for obtaining nk cell specific expression
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014153270A1 (en) 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US9803017B2 (en) 2013-07-05 2017-10-31 University Of Washington Through Its Center For Commercialization Soluble MIC neutralizing monoclonal antibody for treating cancer
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015164675A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016033570A1 (en) 2014-08-28 2016-03-03 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for cd19
WO2016064929A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016176651A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016201304A1 (en) 2015-06-10 2016-12-15 Nantkwest, Inc. Modified nk-92 cells for treating cancer
WO2017100709A1 (en) 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
WO2018165291A1 (en) 2017-03-08 2018-09-13 Nantkwest, Inc. MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
WO2018183385A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019018603A2 (en) 2017-07-19 2019-01-24 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
WO2019028337A1 (en) 2017-08-04 2019-02-07 Nantkwest, Inc. TREATMENT AND INHIBITION OF LEUKEMIA USING NK-92 CELLS
WO2019032929A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2020033927A2 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. AAC39849.1
"II DNA Cloning", vol. 45, 1985, IRL PRESS
"Immunol. Meth.", vol. I, II, 1979, ACAD. PRESS
A. L. LEHNINGER: "Biochemistry", 1975, WORTH PUBLISHERS, pages: 73 - 75
AGNEW, CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
BAUER ET AL., GENE, vol. 37, 1985, pages 73
BERNE ET AL.: "Dynamic Light Scattering with Applications to Chemistry, Biology and Physics", 2000, COURIER DOVER PUBLICATIONS
CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004
CRAIK, BIOTECHNIQUES, January 1985 (1985-01-01), pages 12 - 19
CRISTINA CALDAS ET AL: "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen.", MOLECULAR IMMUNOLOGY, vol. 39, no. 15, 1 May 2003 (2003-05-01), pages 941 - 952, XP055025334, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(03)00022-1 *
DU J ET AL: "Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 382, no. 4, 17 October 2008 (2008-10-17), pages 835 - 842, XP026805063, ISSN: 0022-2836, [retrieved on 20080731], DOI: 10.1016/J.JMB.2008.07.075 *
ENDO ET AL., BIOTECHNOL. ADV., vol. 21, 2003, pages 695 - 713
GORMAN ET AL., PNAS, vol. 79, 1982, pages 6777
GROSSCHEDL ET AL., CELL, vol. 41, 1985, pages 885
HITZMAN ET AL., 11TH INTL. CONF. YEAST, GENETICS & MOLEC. BIOL., 1982
HOLLIGER, R ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 64446448
HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071
HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
JEWETT A. ET AL., HUM. IMMUNOL., vol. 64, 2003, pages 505 - 520
JIANHUA X ET AL: "Modification in framework region I results in a decreased affinity of chimeric anti-TAG72 antibody", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 28, no. 1-2, 1 January 1991 (1991-01-01), pages 141 - 148, XP023681971, ISSN: 0161-5890, [retrieved on 19910101], DOI: 10.1016/0161-5890(91)90097-4 *
JOHNSTON ET AL., SCIENCE, vol. 242, 1988, pages 1038 - 1041
KAMATRAFIQUE, ANALYTICAL BIOCHEMISTRY, vol. 536, 2017, pages 16 - 31
KIPRIYANOV, S. M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101
KIPRIYANOV, S. M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 10471058
MAGALHAES ET AL., EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 19, no. 8, 2019, pages 811 - 827
MILLER ET AL., BIO/TECHNOL., vol. 7, 1989, pages 698
MOKYR ET AL., CANCER RES, vol. 58, 1998, pages 5301 - 5304
OKAYAMA ET AL., MOL. CELL. BIOL., vol. 3, 1983, pages 280
OTT ET AL.: "ASCO Educational Book, Developmental Immunotherapy and Tumor Immunobiology", 2019, pages: e70 - 78
PANKA D J ET AL: "VARIABLE REGION FRAMEWORK DIFFERENCES RESULT IN DECREASED OR INCREASED AFFINITY OF VARIANT ANTI-DIGOXIN ANTIBODIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 85, no. 9, 1 May 1988 (1988-05-01), pages 3080 - 3084, XP000611718, ISSN: 0027-8424, DOI: 10.1073/PNAS.85.9.3080 *
POLJAK, R. J ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
ROHAAN ET AL., VIRCHOWS ARCHIV, vol. 474, 2019, pages 449 - 461
SCOPES: "Protein Purification", 1982, SPRINGER-VERLAG
SITARAMAN ET AL., METHODS MOL. BIOL., vol. 498, 2009, pages 229 - 44
SMITH ET AL.: "Genetic Engineering: Principles and Methods", 1981, PLENUM PRESS
SPIRIN, TRENDS BIOTECHNOL., vol. 22, 2004, pages 538 - 45
TOPALIAN ET AL.: "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy", CANCER CELL, vol. 27, 13 April 2015 (2015-04-13), pages 450 - 61, XP055372181, DOI: 10.1016/j.ccell.2015.03.001
WALDER ET AL., GENE, vol. 42, 1986, pages 133
WARD ET AL., NATURE, vol. 334, 1989, pages 544 - 54
WEIDLE ET AL., GENE, vol. 51, 1987, pages 21

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023076883A1 (en) * 2021-10-27 2023-05-04 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
EP4423140A4 (en) * 2021-10-27 2025-10-01 Samyang Biopharm Usa Inc ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS
WO2023225626A3 (en) * 2022-05-20 2024-06-13 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Also Published As

Publication number Publication date
JP2023532852A (ja) 2023-08-01
CA3184940A1 (en) 2022-01-13
KR20230012072A (ko) 2023-01-25
CN116249716A (zh) 2023-06-09
AU2021305084A1 (en) 2023-02-02
US12139539B2 (en) 2024-11-12
KR20230152783A (ko) 2023-11-03
TW202216776A (zh) 2022-05-01
KR102594083B1 (ko) 2023-10-25
EP4178678A1 (en) 2023-05-17
US20230235065A1 (en) 2023-07-27
US20250026837A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
EP3431102A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
CN112300280B (zh) 一种抗pd-1抗体及其医药用途
US20170247463A1 (en) Modulating Agonistic TNFR Antibodies
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
AU2020267349A1 (en) CLEC12a-binding polypeptides and uses thereof
KR102690145B1 (ko) 항ctla-4 항체의 사용
AU2020268827A1 (en) CD33-binding polypeptides and uses thereof
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
US20250230246A1 (en) Anti-mic antibodies with variant fc domains
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
TW202304984A (zh) 抗人類ｃｘｃｒ５抗體及其用途
HK40087490A (zh) Mic抗体和结合剂及其使用方法
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
US12325749B2 (en) Anti-PD-L1 antibody and use thereof
TW202216764A (zh) 抗ctla-4抗體及其之用途
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
EA039429B1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3xcd20

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21748734

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022578860

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227046132

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3184940

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021305084

Country of ref document: AU

Date of ref document: 20210706

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021748734

Country of ref document: EP

Effective date: 20230207